Perceptive’s Alzheimer’s imaging aims to cut costs

By Nick Taylor

- Last updated on GMT

Related tags Magnetic resonance imaging Medical imaging

Perceptive Informatics has expanded its offering for trials involving Alzheimer's disease with a new medical imaging method, which it claims produces higher quality, reproducible and regulatory compliant assessments.

Aging populations in many Western countries have expanded the potential market for Alzheimer’s treatments and Perceptive believes its new imaging methodology can assist in this search.

The imaging technique uses a novel method to measure ventricular change, which Perceptive believes accurately reflects brain atrophy, to provide users with information to make better and quicker development decisions.

Kenneth Faulkner, vice president of medical imaging at Perceptive Informatics, said: "It is more critical than ever that biopharmaceutical companies have the ability to make accurate go/no go decisions as early as possible for new compounds​.

Medical imaging is increasingly being used as a surrogate endpoint or biomarker of drug efficacy in all phases of CNS trials. With this new methodology, we believe that Perceptive's therapeutic area experts are able to help sponsors advance neuroimaging and bring important CNS treatments to patients sooner​."

Forming the methodology

Perceptive developed the methodology using Medical Resonance Imaging (MRI) scans from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Analysing this suggested that measuring ventricular change provides the most robust way of assessing Alzheimer’s progression.

This understanding formed the basis of the medical imaging methodology, which Perceptive believes can reduce the time, risk and costs associated with clinical development of Alzheimer's treatments.

James Paskavitz, medical director at Perceptive added that the image data “informs early phase decisions and is reproducible for later phase, multi-centre trials​”.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Related suppliers

Follow us

Products

View more

Webinars